Phenprocoumon
Systematic (IUPAC) name | |
---|---|
(RS)-4-hydroxy-3-(1-phenylpropyl)-2H-chromen-2-one | |
Clinical data | |
Trade names | Marcoumar, Marcumar, Falithrom |
AHFS/Drugs.com | International Drug Names |
MedlinePlus | a699003 |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 99% |
Metabolism | hepatic to inactive metabolites |
Biological half-life | 5 to 6 days |
Identifiers | |
CAS Number | 435-97-2 |
ATC code | B01AA04 (WHO) |
PubChem | CID 9908 |
IUPHAR/BPS | 6839 |
DrugBank | DB00946 |
ChemSpider | 10441592 |
UNII | Q08SIO485D |
KEGG | D05457 |
ChEBI | CHEBI:50438 |
ChEMBL | CHEMBL1465 |
Chemical data | |
Formula | C18H16O3 |
Molar mass | 280.318 g/mol |
| |
| |
(verify) |
Phenprocoumon (marketed under the brand names Marcoumar, Marcumar and Falithrom) is a long-acting oral anticoagulant drug, a derivative of coumarin. It is a vitamin K antagonist that inhibits coagulation by blocking synthesis of coagulation factors II, VII, IX and X. It is used for the prophylaxis and treatment of thromboembolic disorders (thrombosis/pulmonary embolism). It is the standard coumarin used in Germany.
Phenprocoumon is a 4-hydroxycoumarin and inhibits vitamin K epoxide reductase.[1]
References
- ↑ Phenprocoumon at PharmGKB
External links
|
|
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.